Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Nycomed Expects More Dealmaking in Russia; Prepares Daxas Rollout In Turkey

This article was originally published in PharmAsia News

Executive Summary

Swiss drug maker Nycomed Pharma AS aims to increase revenues from emerging markets by 150% by 2015. The Zurich-based private equity-owned company has seen double-digit growth in Russia and Latin American markets in the past year, and now it is preparing for more deal-making from Moscow and a major product launch in Turkey to accelerate the growth

Related Content




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts